WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage clinical development, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria. The researchers concluded that eravacycline, which is presently being studied in Phase 3 trials for complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), demonstrated excellent in vitro activity against Gram-negative MDR strains of E. coli, Klebsiella pnuemoniae, Enterobacter spp., and Acinetobacter baumannii. IDWeek takes place from October 8 – 12 in Philadelphia at The Pennsylvania Convention Center.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
